Connection

PEDRO PIEDRA to Antibodies, Monoclonal, Humanized

This is a "connection" page, showing publications PEDRO PIEDRA has written about Antibodies, Monoclonal, Humanized.
  1. Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
    View in: PubMed
    Score: 0.175
  2. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. MMWR Morb Mortal Wkly Rep. 2024 Mar 07; 73(9):209-214.
    View in: PubMed
    Score: 0.164
  3. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. MAbs. 2013 Mar-Apr; 5(2):263-9.
    View in: PubMed
    Score: 0.076
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.